160 related articles for article (PubMed ID: 31692290)
1. Identification of a novel somatic mutation of POU6F2 by whole-genome sequencing in prolactinoma.
Miao Y; Li C; Guo J; Wang H; Gong L; Xie W; Zhang Y
Mol Genet Genomic Med; 2019 Dec; 7(12):e1022. PubMed ID: 31692290
[TBL] [Abstract][Full Text] [Related]
2. [Melatonin inhibits the proliferation of pituitary prolactin-secreting tumor by suppressing the enhancer elements mutation of PRL gene in the rat].
Gao L; Yang QH; Xu RK
Sheng Li Xue Bao; 2005 Jun; 57(3):319-27. PubMed ID: 15968426
[TBL] [Abstract][Full Text] [Related]
3. Genomic and transcriptomic analysis of pituitary adenomas reveals the impacts of copy number variations on gene expression and clinical prognosis among prolactin-secreting subtype.
Chen Y; Gao H; Xie W; Guo J; Fang Q; Zhao P; Liu C; Zhu H; Wang Z; Wang J; Gui S; Zhang Y; Li C
Aging (Albany NY); 2020 Dec; 13(1):1276-1293. PubMed ID: 33472173
[TBL] [Abstract][Full Text] [Related]
4. Lower PRDM2 expression is associated with dopamine-agonist resistance and tumor recurrence in prolactinomas.
Gao H; Wang F; Lan X; Li C; Feng J; Bai J; Cao L; Gui S; Hong L; Zhang Y
BMC Cancer; 2015 Apr; 15():272. PubMed ID: 25884948
[TBL] [Abstract][Full Text] [Related]
5. The Genomic Landscape of Sporadic Prolactinomas.
De Sousa SMC; Wang PPS; Santoreneos S; Shen A; Yates CJ; Babic M; Eshraghi L; Feng J; Koszyca B; Roberts-Thomson S; Schreiber AW; Torpy DJ; Scott HS
Endocr Pathol; 2019 Dec; 30(4):318-328. PubMed ID: 31473917
[TBL] [Abstract][Full Text] [Related]
6. PBK/TOPK Inhibitor Suppresses the Progression of Prolactinomas.
Zhu K; Cheng X; Wang S; Zhang H; Zhang Y; Wang X; Chen Y; Wu J
Front Endocrinol (Lausanne); 2021; 12():706909. PubMed ID: 35126305
[TBL] [Abstract][Full Text] [Related]
7. Pituitary prolactin-secreting tumor formation: recent developments.
Xu RK; Wu XM; Di AK; Xu JN; Pang CS; Pang SF
Biol Signals Recept; 2000; 9(1):1-20. PubMed ID: 10686432
[TBL] [Abstract][Full Text] [Related]
8. Heregulin regulates prolactinoma gene expression.
Vlotides G; Cooper O; Chen YH; Ren SG; Greenman Y; Melmed S
Cancer Res; 2009 May; 69(10):4209-16. PubMed ID: 19401448
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic response to pazopanib: case report and literature review on molecular abnormalities of aggressive prolactinomas.
Medina EJ; Zohdy YM; Porto E; Revuelta Barbero JM; Bray D; Maldonado J; Rodas A; Mayol M; Morales B; Neill S; Read W; Pradilla G; Ioachimescu A; Garzon-Muvdi T
Front Endocrinol (Lausanne); 2023; 14():1195792. PubMed ID: 37529607
[TBL] [Abstract][Full Text] [Related]
10. ras mutations in human prolactinomas and pituitary carcinomas.
Cai WY; Alexander JM; Hedley-Whyte ET; Scheithauer BW; Jameson JL; Zervas NT; Klibanski A
J Clin Endocrinol Metab; 1994 Jan; 78(1):89-93. PubMed ID: 8288721
[TBL] [Abstract][Full Text] [Related]
11. [Analysis of different mutations in regulatory sequence of prolactin gene during the formation of 17 beta-estradiol-induced prolactinoma in eutopic and ectopic pituitary of rats].
Zhang FZ; Yang QH; Mao YC; Xu RK
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2006 Dec; 28(6):822-7. PubMed ID: 17260475
[TBL] [Abstract][Full Text] [Related]
12. The Balance of PI3K and ERK Signaling Is Dysregulated in Prolactinoma and Modulated by Dopamine.
Roof AK; Jirawatnotai S; Trudeau T; Kuzyk C; Wierman ME; Kiyokawa H; Gutierrez-Hartmann A
Endocrinology; 2018 Jun; 159(6):2421-2434. PubMed ID: 29726995
[TBL] [Abstract][Full Text] [Related]
13. Leukemia inhibitory factor regulates prolactin secretion in prolactinoma and lactotroph cells.
Ben-Shlomo A; Miklovsky I; Ren SG; Yong WH; Heaney AP; Culler MD; Melmed S
J Clin Endocrinol Metab; 2003 Feb; 88(2):858-63. PubMed ID: 12574225
[TBL] [Abstract][Full Text] [Related]
14. [Homeoproteins and pituitary adenoma].
Barlier A; Pellegrini-Bouiller I; Gunz G; Jaquet P; Enjalbert A
Ann Endocrinol (Paris); 1997; 58(1):3-10. PubMed ID: 9207961
[TBL] [Abstract][Full Text] [Related]
15. Evolution of an aggressive prolactinoma into a growth hormone secreting pituitary tumor coincident with GNAS gene mutation.
Lania AG; Ferrero S; Pivonello R; Mantovani G; Peverelli E; Di Sarno A; Beck-Peccoz P; Spada A; Colao A
J Clin Endocrinol Metab; 2010 Jan; 95(1):13-7. PubMed ID: 19890024
[TBL] [Abstract][Full Text] [Related]
16. Loss of 15-hydroxyprostaglandin dehydrogenase indicates a tumor suppressor role in pituitary adenomas.
Bai JW; Wang Z; Gui SB; Zhang YZ
Oncol Rep; 2012 Aug; 28(2):714-20. PubMed ID: 22580984
[TBL] [Abstract][Full Text] [Related]
17. Hereditary pituitary prolactinomas: a new rat model.
Chedid A; Hoversland RC; Chejfec G; McCune SA; Jurin RR; Evans EE
Acta Endocrinol (Copenh); 1988 Dec; 119(4):535-42. PubMed ID: 3059738
[TBL] [Abstract][Full Text] [Related]
18. [Experimental investigation on the etiology and pathogenesis of pituitary prolactin-secreting tumor].
Wu XM
Sheng Li Ke Xue Jin Zhan; 2000 Jan; 31(1):43-6. PubMed ID: 12532766
[TBL] [Abstract][Full Text] [Related]
19. Pathogenesis of prolactinomas.
Spada A; Mantovani G; Lania A
Pituitary; 2005; 8(1):7-15. PubMed ID: 16411063
[TBL] [Abstract][Full Text] [Related]
20. Somatic SF3B1 hotspot mutation in prolactinomas.
Li C; Xie W; Rosenblum JS; Zhou J; Guo J; Miao Y; Shen Y; Wang H; Gong L; Li M; Zhao S; Cheng S; Zhu H; Jiang T; Ling S; Wang F; Zhang H; Zhang M; Qu Y; Zhang Q; Li G; Wang J; Ma J; Zhuang Z; Zhang Y
Nat Commun; 2020 May; 11(1):2506. PubMed ID: 32427851
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
